Large molecule drugs were often less defined as they were of biological origin e.g., due to posttranslational modifications and impurities. With the increasing power of analytical and preparative techniques and with the advent of molecularly exactly defined oligonucleotides , the distinction of ......
Small MoleculeDrugs No matter where you are on the path of bringing your small molecule discovery to market, DataRevive has the in-house expertise and understanding of the FDA approval methodologies needed to optimize regulatory compliance and filings, helping you bring your small molecule drug to ...
drugs. Since its foundation, Fochon Pharmaceuticals has built a significant R&D pipeline focusing on the research of innovator drugs urgently needed for clinical anti-tumor and metabolic diseases, which consists of drug candidates targeting ALK/ROS1, BCL-2, BTK, pan-TRK (1st & 2nd generation), ...
Small molecule drugs specifically targeting peripheral itch transmission, e.g. peripherally selective 魏-opioid receptors agonists and neurokinin 1 receptors antagonists, have so far been unable to improve AD-related pruritus when applied systemically, possibly because of the lack of CNS activity. ...
106 www.neuropsychopharmacology.org REVIEW Drugability of Extracellular Targets: Discovery of Small Molecule Drugs Targeting Allosteric, Functional, and Subunit-Selective Sites on GPCRs and Ion Channels Dimitri E Grigoriadis*,1, Samuel R J Hoare1, Sandra M Lechner1, Deborah H Slee1 and John A ...
Currently, two main strategies against the virus are available, which are vaccination and small molecule anti-influenza drugs. Anti-influenza small molecule drugs present the first line of protection against the virus during an epidemic outbreak, especially in the early stages, as an effective ...
Investigational New Drugs (2013) Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature Ph. Kaldrymides I. Kostoglou-Athanassiou N. Ziras Endocrine (2010) New therapeutic approaches to treat medullary thyroid carcinoma Martin Sc...
Pfizer Inc. is ending work on oral GLP-1 candidate danuglipron for weight loss following the report of a single potentially drug-induced liver injury, a move that appears to open the door for other firms working on oral therapies in the high-dollar obesity space, even as industry watchers ...
Regarding tolerability, QTc prolongation is frequently observed for most of approved SMIs, and drugs with a potential to prolong the QTc interval and CYP3A4 inhibitors should be avoided and replaced by alternative treatments. In this study, we critically assess the DDIs of SMIs, and we summarize...
Researchers at Mayo Clinic have demonstrated in a mouse model that their recently developed synthetic peptide carrier is a potential delivery vehicle for brain cancer chemotherapy drugs and other neurological medications. The findings appear in PLOS ONE.